share_log

Virpax Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Dhaliwal Jatinder

Virpax Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Dhaliwal Jatinder

Virpax製藥 | 3：首次持股聲明-董事 Dhaliwal Jatinder
美股SEC公告 ·  07/09 16:06

Moomoo AI 已提取核心訊息

Jatinder Dhaliwal, a director and 10% owner of Virpax Pharmaceuticals, filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated July 5, 2024, indicates that Dhaliwal does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Vinay Shah on behalf of Dhaliwal, was completed on July 9, 2024. This standard disclosure is part of the regulatory compliance for individuals in significant positions within publicly traded companies, ensuring transparency in ownership stakes.
Jatinder Dhaliwal, a director and 10% owner of Virpax Pharmaceuticals, filed an initial statement of beneficial ownership with the SEC, as per Form 3 requirements. The filing, dated July 5, 2024, indicates that Dhaliwal does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Vinay Shah on behalf of Dhaliwal, was completed on July 9, 2024. This standard disclosure is part of the regulatory compliance for individuals in significant positions within publicly traded companies, ensuring transparency in ownership stakes.
Virpax藥品公司的董事兼10%股東Jatinder Dhaliwal根據Form 3規定向SEC提交了受益所有權的初始聲明。該申報文件的日期爲2024年7月5日，表明Dhaliwal不存在任何該公司的非衍生或衍生證券的受益所有權。該表格由代理律師Vinay Shah代表Dhaliwal於2024年7月9日完成。這是公開交易公司內部重要職位個人監管合規的標準披露，保證公司所有權持股的透明度。
Virpax藥品公司的董事兼10%股東Jatinder Dhaliwal根據Form 3規定向SEC提交了受益所有權的初始聲明。該申報文件的日期爲2024年7月5日，表明Dhaliwal不存在任何該公司的非衍生或衍生證券的受益所有權。該表格由代理律師Vinay Shah代表Dhaliwal於2024年7月9日完成。這是公開交易公司內部重要職位個人監管合規的標準披露，保證公司所有權持股的透明度。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間